SYK
HealthcareStryker Corporation · Medical - Devices · $125B
What is Stryker Corporation?
Stryker Corporation is a large-cap medical technology company headquartered in Portage, Michigan, serving hospitals, surgeons, and healthcare facilities worldwide with a broad portfolio of devices and equipment.
Stryker generates revenue through two main segments. Its Orthopaedics and Spine segment provides implants for hip, knee, trauma, and spinal procedures. Its MedSurg and Neurotechnology segment covers surgical equipment, navigation systems, emergency medical products, and minimally invasive neurovascular devices — selling directly to hospitals and healthcare providers.
Stryker was founded in 1980 and is headquartered in Portage, US.
- Joint replacement implants (hip and knee)
- Spinal implant and deformity correction systems
- Surgical equipment and navigation technology
- Neurovascular and stroke treatment devices
Is SYK a Good Stock to Buy?
UQS Score rates SYK as Good overall.
Stryker's Quality pillar reflects a well-established business with consistent operational execution across its diversified medical device segments. The company's broad product reach across orthopaedics, neurotechnology, and surgical equipment supports a stable revenue base.
The Moat, Growth, and Valuation pillars all register as Neutral, suggesting the stock does not stand out as deeply discounted or rapidly expanding relative to sector peers.
Sign up to see the full pillar breakdown and detailed financial metrics behind SYK's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SYK pay dividends?
Yes — Stryker Corporation pays a dividend.
Stryker pays a regular dividend, reflecting the company's ability to return capital to shareholders alongside ongoing investment in its product portfolio. This cadence is typical of mature, cash-generative medical technology companies with diversified revenue streams.
When does SYK report earnings?
Stryker Corporation reports earnings on a quarterly cadence, consistent with US-listed large-cap equities.
Stryker's dual-segment structure provides exposure to both elective procedure volumes and hospital capital spending cycles. Performance across quarters tends to reflect broader trends in surgical activity and healthcare facility investment.
For the most recent quarter's results, visit Stryker Corporation's investor relations page directly.
SYK Price History
+22.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Stryker Corporation?
Based on Stryker Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Stryker do?
Stryker is a medical technology company that makes implants for joint replacements and spinal procedures, as well as surgical equipment, navigation systems, and neurovascular devices. It sells to hospitals, surgeons, and healthcare facilities globally through its own subsidiaries and distribution network.
Does SYK pay dividends?
Yes, Stryker pays a regular dividend. This is consistent with its profile as a mature, large-cap medical device company that generates steady cash flows. For current yield and payment schedule details, check Stryker's investor relations page.
When does SYK report earnings?
Stryker reports on a quarterly basis, as is standard for US-listed companies. For the exact dates of upcoming earnings releases, refer to Stryker's official investor relations page.
Is SYK a good stock to buy?
UQS Score rates SYK as Good overall, with Quality as its strongest pillar. Moat, Growth, and Valuation all sit at Neutral. Whether it fits your portfolio depends on your goals — the full pillar analysis is available to Pro members on uqs-score.com.
Is SYK overvalued?
SYK's Valuation pillar is rated Neutral, meaning it does not appear deeply discounted or significantly stretched relative to its fundamentals. For a complete valuation breakdown, Pro members can access the full metrics on uqs-score.com.
What is SYK's market cap bracket?
Stryker is classified as a large-cap company, reflecting its scale and long-standing position as one of the major players in the global medical technology sector.
Is SYK a long-term quality indicator?
UQS Score's long-term quality view is captured across five pillars. SYK's Good overall rating — anchored by its Quality pillar — suggests a business with durable operational characteristics, though Neutral Growth and Moat ratings indicate areas worth monitoring over time.
What sector does SYK belong to?
Stryker operates in the Healthcare sector, specifically within medical technology. It competes alongside companies like Medtronic, Abbott Laboratories, and Boston Scientific in the broader medical devices and equipment space.
Unlock Full SYK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics behind Stryker's Good rating
- ✓Compare SYK side-by-side with Medtronic, Abbott, and Boston Scientific
- ✓Get the complete analyst view available to Pro members
Pro Analysis
SYK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | 30.9 | 14.3 | 50.0 | 0.0 | 36.9 | 61.7 | -24.1 |
| Jul 31, 2026 | 55.0 | 59.2 | 50.0 | 52.7 | 60.6 | 53.8 | +0.9 |
| Jul 26, 2026 | 54.1 | 61.0 | 50.0 | 52.7 | 49.8 | 55.4 | -0.4 |
| Jul 25, 2026 | 54.5 | 61.0 | 50.0 | 52.7 | 49.8 | 58.2 | -0.3 |
| Jul 24, 2026 | 54.8 | 61.3 | 50.0 | 52.7 | 49.8 | 60.0 | -0.3 |
| Jul 23, 2026 | 55.1 | 61.6 | 50.0 | 52.7 | 49.8 | 61.4 | +0.1 |
| Jul 22, 2026 | 55.0 | 61.4 | 50.0 | 52.7 | 49.8 | 61.2 | +0.2 |
| Jul 21, 2026 | 54.8 | 61.3 | 50.0 | 52.7 | 49.8 | 60.0 | -0.4 |
| Jul 20, 2026 | 55.2 | 61.3 | 50.0 | 52.7 | 49.8 | 62.3 | 0.0 |
| Jul 18, 2026 | 55.2 | 61.3 | 50.0 | 52.6 | 49.8 | 62.3 | +0.4 |
SYK — Pillar Breakdown
Quality
— 14.3/100 (25%)Stryker Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Stryker Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Stryker Corporation has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 61.7/100 (15%)Stryker Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
How many years of FCF the market cap represents.
Moat
— 50/100 (25%)Stryker Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SYK.
Score Composition
Financial Data
More Stock Analysis
How is the SYK UQS Score Calculated?
The UQS (Unified Quality Score) for Stryker Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Stryker Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Stryker Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.